Synthesis and Evaluation of Aliphatic-chain Hydroxamates Capped with Osthole Derivatives as Histone Deacetylase Inhibitors

Shih-Wei Chao (趙世偉)\textsuperscript{a}, Ching-Chow Chen\textsuperscript{b}, Chen-Yui Yang\textsuperscript{c}, Yun-Chieh Lin\textsuperscript{b}, Chia-Chun Yu\textsuperscript{c}, Jih-Hwa Guh\textsuperscript{c}, Chiao-I Kuo\textsuperscript{d}, Ping Yang\textsuperscript{a}, Chung-I Chang\textsuperscript{d*}, Wei-Jan Huang\textsuperscript{a*}

\textsuperscript{a}Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei 110, Taiwan
\textsuperscript{b}Department of Pharmacology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
\textsuperscript{c}School of Pharmacy, College of Medicine, National Taiwan University, Taipei 100, Taiwan
\textsuperscript{d}Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan

Our previous studies have demonstrated that osthole, a Chinese herbal compound, could be incorporated into the hydroxycinnamamide scaffold of LBH-589, a potent HDAC inhibitor, as an effective hydrophobic cap; the resulting compounds showed significant potency against several HDAC isoforms. Here, we presented a series of osthole derivatives fused with the aliphatic-hydroxamate core of suberoylanilide hydroxamic acid (SAHA), a clinically-approved HDAC inhibitor. Several compounds showed potent activity against nuclear HDACs comparable. Further assays against individual HDAC isoforms revealed that some compounds showed not only SAHA-like activity towards HDAC1, -4 and -6, they inhibited HDAC8 by log difference than SAHA and thus exhibited a broader HDAC inhibition spectrum. Among them, compound 6g showed multiple significant cellular effects towards human prostate cancer cells.